{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-106669","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.776762+00:00","generated_at":"2026-05-17T00:10:38.251328+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"confidence":"high","headline":"Marker Therapeutics appoints Kathryn Penkus Corzo to Board; CEO granted 250,000 options","bullets":["Kathryn Penkus Corzo appointed to Board effective Nov 1, 2025; she brings 30+ years of biopharma leadership.","Corzo currently President/COO of bit.bio; previously Head of Oncology Cell Therapy at Takeda Ventures.","Corzo received 147,611 stock options as non-employee director compensation, vesting over 36 months.","CEO Juan Vera granted 250,000 stock options, vesting annually over 4 years under the 2020 Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-106669","json":"https://secwatch.observer/filing/0001104659-25-106669.json","markdown":"https://secwatch.observer/filing/0001104659-25-106669.md","text":"https://secwatch.observer/filing/0001104659-25-106669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925106669/0001104659-25-106669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925106669/tm2530129d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:10:38.251328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}